

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act o equired to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION **DISCLOSURE** STATEMENT BY APPLICANT

Complete if Known Application Number 10/075,257 Filing Date February 15, 2002 First Named Inventor Yoram REITER Group Art Unit VANDERVEGT, FRANCOIS P Examiner Name

(use as many sheets as necessary)

(use us	muny sneets as necessary)				
	1 Of	1	Attorney Docket Number	02/23338	
_					
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				_ T ²
1	Mage et al "A Recombinant, Soluble, Single-Chain Class 1 Major Histocompatibility Complex Molecule with Biological Activity", PNAS, 89:				
2	Uger et al "Covalent Linka				
		· <u></u>			
	·				
					_
	Cite No. ¹	Cite No. Include name of the author (in Citem (book, magazine, journal, spublication) Mage et al "A Recombinant Histocompatibility Completed 10658-10662, 1992. Uger et al "Covalent Linkat Antigeniticity of Suboptime	1 Of 1 OTHER PRIOR ART – NON PATENT Cite No. I Include name of the author (in CAPITAL LETTER: item (book, magazine, journal, serial symposium, c publisher, city and/or constitution of the publisher of the publ	1 Of 1 Attorney Docket Number OTHER PRIOR ART – NON PATENT LITERATURE DOCU Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when app item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volum publisher, city and/or country where published. 1 Mage et al "A Recombinant, Soluble, Single-Chain Class 1 Major Histocompatibility Complex Molecule with Biological Activity", P. 10658-10662, 1992. 2 Uger et al "Covalent Linkage to β2-Microglobulin Enhances the M. Antigeniticity of Suboptimal CTL Epitopes", The Journal of Immuni	1 Of 1 Attorney Docket Number 02/23338 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Cite No. I Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. I Mage et al "A Recombinant, Soluble, Single-Chain Class 1 Major Histocompatibility Complex Molecule with Biological Activity", PNAS, 89: 10658-10662, 1992. Uger et al "Covalent Linkage to \$2-Microglobulin Enhances the MHC Stability and Antigeniticity of Suboptimal CTL Epitopes", The Journal of Immunology, 162:

Examiner	/F Pierre VanderVegt/	Date	12/03/2008
Signature		Considered	12/00/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450